AltruBio Gathers Funds as Biotechs Aim for Next Blockbuster Anti-Inflammatory Therapy
Wall Street Journal
Biotechnology startup AltruBio has secured fresh capital to develop a drug for ulcerative colitis as drugmakers compete to develop the next blockbuster therapy for this and other inflammatory diseases.